Bianchi Lab

Physician-Scientist running a hypothesis-driven research program to develop effective therapies for Amyloidosis and Myeloma patients. @brighamheme @harvardmed

[Mark Lewis, MD, FASCO @marklewismd]

Cheers, chills, and a standing ovation when RASolute 302 showed unprecedented survival on daraxonrasib for patients with progressive pancreatic cancer

Seldom do you sense you’re witnessing a historic moment in cancer care but this feels like ras targeting has arrived

#ASCO26

[Bianchi Lab @TheBianchiLab]

Well done @SLentzsch ! Your unwavering dedication to research and patient care in AL amyloidosis (and multiple myeloma) is inspiring! Congrats to all involved and on to next..

[Suzanne Lentzsch, MD, PhD @SLentzsch]

One of the most rewarding and emotional moments of my career took place at #ASCO2026. In 2015, I started the first-in-human trial of 11-1F4 (now anselamimab), supported by a small FDA grant and @columbiacancer. At the time, the path forward was far from certain. We faced limited funding, strong competition from Prothena’s NEOD001 program, and considerable skepticism from industry given the rarity of AL amyloidosis and the fact that competing programs were already much further advanced in development.

Despite these challenges, we continued to move forward step by step. The phase 1 study demonstrated encouraging results, ultimately leading to the founding and funding of Caelum Biosciences in 2017 and the launch of the subsequent phase 2 and phase 3 studies. Those efforts were later advanced and completed through the commitment and resources of @AlexionCARES and @AstraZenecaUS.

@ASCO I had the privilege of chairing the session when the final phase 3 results where presented by Dr. Wechalekar, which demonstrated a significant overall survival benefit in patients with stage IIIA/IIIB κ AL amyloidosis🙌. Seeing a scientific concept evolve from an investigator-initiated first-in-human study into a positive phase 3 trial is extraordinarily rewarding.

This achievement reflects the dedication of countless patients, supporters🙏@MorieGertz, investigators, research staff, industry partners, and advocates who believed in this program over many years. It is also a powerful reminder of why we do translational research-to transform promising science into therapies that meaningfully improve patients' lives.

#ASCO2026 #ALAmyloidosis @Amyloidosis_ARC @Amyloidosisfdn @AmyloidosisSupp @ISA_Amyloidosis

[Victor H Jimenez-Zepeda @vhugo8762]

Efficacy and Safety of Anselamimab in Immunoglobulin Light Chain Amyloidosis: Results From the Randomized CARES Trials | Journal of Clinical Oncology https://t.co/oft4Rn1S2j

More is needed but absolutely thrilled to see the amyloid community running these trials.

[awechalekar @awechalekar]

Exciting results for evuzamitide - a new step towards easier diagnosis of cardiac amyloidosis - Phase III REVEAL study met its primary endpoints demonstrating sensitivity and specificity of iodine 124 evuzamitide (I 124 evuzamitide) positron emission tomography computed tomography (PET/ CT) for the diagnosis of cardiac amyloidosis - congratulations @DorbalaSharmila on leading this groundbreaking research @Bayer @Amyloidosis_ARC @ISA_Amyloidosis

[awechalekar @awechalekar]

Anselamimab is a potential new therapeutic in Kappa AL - abstract now available - countdown to full presentation @ASCO and simultaneous publication @JCO_ASCO on Friday 29th - Anselamimab treated patients with κ iFLC had a 62% reduction in ACM (HR = 0.38; 95% CI, 0.17, 0.86; nominal P = 0.012) and a 71% reduction in risk for CVH (estimated CVH rate ratio = 0.29; 95% CI, 0.10, 0.87; nominal P = 0.028). Patients with λ iFLC had a 10% reduction in risk for CVH; none in ACM. @AlexionPharma @ISA_Amyloidosis @Amyloidosis_ARC

[Bianchi Lab @TheBianchiLab]

Congrats @lane_andy !

[Dana-Farber @DanaFarber]

Andrew Lane, MD, PhD, recently assumed the role of Chief, Division of Hematologic Neoplasia. We look forward to the continued growth and success of the division under his leadership. Please join us in congratulating him on this new role.

[Raj Chakraborty @rajshekharucms]

The treatment landscape for AL #Amyloidosis has been transformed—but how do we assess prognosis and progression in the current era? We reviewed the current evidence on prognostic factors and biomarkers for hematologic and organ progression in this special report, out today in @BloodPortfolio. @Amyloidosis_ARC @YevgeniyBr @awechalekar @MathewMaurer @kristennhsu
https://t.co/UwdIaMm0d6

[Francesco Bianchi @Francesco_Bia]

Best way to start the week: @economoser has decided to join @JohnsHopkins starting July 2027! One more fantastic hire that greatly strengthens our department with expertise in macro labor, public finance and development. Welcome to JHU Chris!

https://t.co/0SUxUrERrc

[Francesco Bianchi @Francesco_Bia]

We had a fantastic @nberpubs boot camp on monetary and fiscal policy, organized by @luigi_bocola, lectures by Luigi, Corina Boar, @ChristianKWolf, and me. Chris' footprints were everywhere. He inspired insightful discussions, even while not being with us anymore.

[Francesco Bianchi @Francesco_Bia]

Woodford: "It is a great loss to our field that we no longer have Chris to lead the way in facing the challenges for macroeconomic modelling that these developments pose." I could not agree more.

[Francesco Bianchi @Francesco_Bia]

I am very happy to announce that @CuiminB will join @JohnsHopkins in July 2026! Cuimin is an outstanding theorist with focus on learning, information, and dynamic games, as well as in behavioral economics and experiments:

https://t.co/5WoisYL97i

[Dana-Farber @DanaFarber]

Congratulations to Benjamin L. Ebert, MD, PhD, who was recently named to @BeckersHR's Greatest Leaders in Healthcare 2026 list. Since becoming president and CEO, he has guided the institute through a period of accelerating change in cancer medicine, developing a strategic plan that builds on our historic strengths while charting bold new directions. View the list here: https://t.co/lYqyIfDHgK

[Dana-Farber @DanaFarber]

Benjamin L. Ebert, MD, PhD, president and CEO, has been elected to @theNASciences in recognition of his distinguished and continuing achievements in cancer research. Please join us in congratulating him on this honor. Learn more: https://t.co/Dw0yBm6rbG

[Dana-Farber News @DanaFarberNews]

At the #AACR26 press conference, @OmarNadeemMD of @DanaFarber presents results of the phase 2 CAR-PRISM clinical trial, the first to investigate CAR T-cell therapy in patients with high-risk smoldering multiple myeloma. The study also published today at @NatureMedicine: https://t.co/4NQ8evY9cW

[Osnat.Itzhaki @ItzhakiOsnat]

Happy to share our simultaneous publication #ACC26 #JACCJournals #CardioOnc describing CV complications associated w/bispecific TCE therapies @TheBianchiLab @ShaiShimony

https://t.co/jqxqXErVfe

[The International Society Of Amyloidosis @ISA_Amyloidosis]

March is Amyloidosis Awareness Month!

We applaud the Amyloidosis Foundation for their continued work to raise awareness and support the amyloidosis community.

Learn more: https://t.co/sUgUsYGDcw

[Francesco Bianchi @Francesco_Bia]

I just heard this news. Chris Sims was a giant of the profession who profoundly changed empirical macro and to some extent finance. He was also my adviser, mentor, and role model. Very generous with his time. Very sad day.

[Francesco Bianchi @Francesco_Bia]

Peter Arcidiacono has officially joined JHU econ and the new school of policy with a joint appointment. I don't think that I need to explain how significant this hire is!

https://t.co/sKaUonP0Gp

[Francesco Bianchi @Francesco_Bia]

I am very happy to announce that Thomas Drechsel @td_econ will be joining @JohnsHopkins econ! A fantastic hire that further strengthens our department. Thomas has a very broad research agenda, spanning Monetary Economics, International Macro, HANK,... Welcome to JHU Thomas!

[Dana-Farber @DanaFarber]

Congratulations to Alice Shaw, MD, PhD, Kimberly Stegmaier, MD, and Matthew Vander Heiden, MD, PhD, on being elected as Fellows of the @AACR Academy Class of 2026. Learn more: https://t.co/Wl1zKnY8q0